Hologic, Inc. Hits New 52-Week High at $75.75, Reflecting Strong Performance

Hologic, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 75.75 on March 5, 2026. This achievement highlights the stock's upward momentum, particularly in a market where the S&P 500 has shown an 18.89% performance over the past year, while Hologic's own performance stands at 2.41%. With a market capitalization of USD 20,132 million, Hologic operates with a price-to-earnings (P/E) ratio of 24.00, reflecting its valuation in the context of its earnings. The company maintains a low debt-to-equity ratio of 0.03, indicating a strong balance sheet and financial stability. Additionally, Hologic's return on equity is reported at 15.39%, showcasing its efficiency in generating profits from shareholders' equity. Despite a dividend yield of 0.00%, the stock's recent performance and its new high may attract attention as it continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry.